Effects_NNS
of_IN
glucocorticoids_NNS
on_IN
lymphocyte_NN
activation_NN
in_IN
patients_NNS
with_IN
steroid-sensitive_JJ
and_CC
steroid-resistant_JJ
asthma_NN
._.

BACKGROUND_NN
:_:
Glucocorticoids_NNS
are_VBP
important_JJ
medications_NNS
used_VBN
to_TO
control_VB
the_DT
airway_NN
inflammation_NN
associated_VBN
with_IN
asthma_NN
._.

Synthetic_JJ
glucocorticoids_NNS
vary_VBP
in_IN
their_PRP$
binding_VBG
affinity_NN
for_IN
the_DT
glucocorticoid_NN
receptor_NN
-LRB-_-LRB-
GCR_NN
-RRB-_-RRB-
._.

METHODS_NNS
:_:
We_PRP
compared_VBD
hydrocortisone_NN
,_,
beclomethasone_NN
dipropionate_NN
,_,
triamcinolone_NN
acetonide_NN
,_,
flunisolide_NN
,_,
and_CC
budesonide_NN
with_IN
regard_NN
to_TO
their_PRP$
capacity_NN
to_TO
inhibit_VB
phytohemagglutinin-induced_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
cell_NN
proliferation_NN
from_IN
six_CD
patients_NNS
with_IN
steroid-sensitive_JJ
asthma_NN
and_CC
seven_CD
patients_NNS
with_IN
steroid-resistant_JJ
asthma_NN
._.

Peripheral_JJ
blood_NN
mononuclear_JJ
cell_NN
GCR_NN
binding_NN
affinities_NNS
for_IN
dexamethasone_NN
and_CC
budesonide_NN
were_VBD
also_RB
determined_VBN
for_IN
both_DT
patient_NN
groups_NNS
by_IN
using_VBG
a_DT
radioligand_NN
binding_NN
assay_NN
and_CC
Scatchard_NN
analysis_NN
._.

RESULTS_NNS
:_:
Dose-dependent_JJ
inhibition_NN
was_VBD
demonstrated_VBN
for_IN
all_DT
glucocorticoids_NNS
in_IN
both_DT
patient_NN
groups_NNS
,_,
with_IN
the_DT
steroid-resistant_JJ
group_NN
requiring_VBG
approximately_RB
2_CD
log-fold_JJ
more_JJR
glucocorticoids_NNS
for_IN
an_DT
equivalent_JJ
degree_NN
of_IN
inhibition_NN
._.

The_DT
mean_JJ
concentrations_NNS
necessary_JJ
to_TO
cause_VB
50_CD
%_NN
inhibition_NN
of_IN
lymphocyte_NN
proliferation_NN
-LRB-_-LRB-
IC50s_NN
-RRB-_-RRB-
for_IN
the_DT
steroid-sensitive_JJ
group_NN
ranged_VBD
from_IN
2_CD
x_CC
10_CD
-LRB-_-LRB-
-10_CD
-RRB-_-RRB-
mol\/L_NN
for_IN
budesonide_NN
to_TO
7_CD
x_CC
10_CD
-LRB-_-LRB-
-8_CD
-RRB-_-RRB-
mol\/L_NN
for_IN
hydrocortisone_NN
,_,
whereas_IN
the_DT
mean_JJ
IC50s_NN
for_IN
the_DT
steroid-resistant_JJ
group_NN
ranged_VBD
from_IN
approximately_RB
2_CD
x_CC
10_CD
-LRB-_-LRB-
-8_CD
-RRB-_-RRB-
mol\/L_NN
for_IN
budesonide_NN
to_TO
greater_JJR
than_IN
10_CD
-LRB-_-LRB-
-6_CD
-RRB-_-RRB-
mol\/L_NN
for_IN
hydrocortisone_NN
._.

In_IN
addition_NN
,_,
a_DT
significant_JJ
correlation_NN
was_VBD
noted_VBN
between_IN
the_DT
degree_NN
of_IN
inhibition_NN
of_IN
lymphocyte_NN
proliferation_NN
-LRB-_-LRB-
IC50_NN
-RRB-_-RRB-
and_CC
the_DT
binding_VBG
affinity_NN
of_IN
dexamethasone_NN
to_TO
the_DT
GCR_NN
._.

Patients_NNS
with_IN
steroid-resistant_JJ
asthma_NN
have_VBP
been_VBN
shown_VBN
to_TO
have_VB
a_DT
reduced_VBN
GCR_NN
binding_NN
affinity_NN
._.

The_DT
GCR_NN
binding_NN
affinity_NN
for_IN
budesonide_NN
was_VBD
significantly_RB
higher_JJR
in_IN
both_DT
groups_NNS
-LRB-_-LRB-
i.e._FW
,_,
lower_JJR
dissociation_NN
constant_NN
-RRB-_-RRB-
than_IN
that_DT
obtained_VBN
for_IN
dexamethasone_NN
._.

CONCLUSION_NN
:_:
These_DT
data_NNS
suggest_VBP
that_IN
glucocorticoids_NNS
such_JJ
as_IN
budesonide_NN
,_,
by_IN
virtue_NN
of_IN
their_PRP$
high_JJ
GCR_NN
binding_NN
affinities_NNS
and_CC
greater_JJR
ability_NN
to_TO
suppress_VB
lymphocyte_NN
proliferation_NN
,_,
may_MD
therefore_RB
be_VB
beneficial_JJ
in_IN
the_DT
management_NN
of_IN
difficult-to-control_JJ
asthma_NN
._.

